Ubiquigent wins o2h Kickstarter Award to support its strategy of enabling the development of novel DUB-targeting compounds
o2h discovery is excited to announce Ubiquigent as a winner of the o2h Kickstarter Competition. Ubiquigent Limited (Ubiquigent), a revenue- and IP-generating drug discovery company dedicated to enabling deubiquitinase (DUB)-focused drug discovery.
As part of the program, o2h discovery will provide Ubiquigent with access to chemists and associated end-to-end expertise to support its development of a novel portfolio of DUB-targeting compounds to enable the development of DUB-based therapeutics in partnership with its pharma and biotech partners.
The development of DUB-targeting compounds is accelerating rapidly as implication, knowledge and understanding of the roles of DUBs in disease are becoming increasingly understood. DUB inhibitors have begun to enter clinical development, and significant investment is being directed towards the development of other DUB-related modalities such as DUB-Targeting Chimeras (DUBTACs) and DUB-Targeting Proteolysis Targeting Chimeras (PROTACs). Despite these advances, access to novel DUB-targeting compounds with which to initiate programs remains challenging.
The development of DUB-targeting compounds is accelerating rapidly as implication, knowledge and understanding of the roles of DUBs in disease are becoming increasingly understood. DUB inhibitors have begun to enter clinical development, and significant investment is being directed towards the development of other DUB-related modalities such as DUB-Targeting Chimeras (DUBTACs) and DUB-Targeting Proteolysis Targeting Chimeras (PROTACs). Despite these advances, access to novel DUB-targeting compounds with which to initiate programs remains challenging. Please click to check out the LinkedIn post
Rishi Shah, Head of Chemistry, Ubiquigent, commented:
“We are delighted to be the latest recipient of an o2h Kickstarter Award. It represents an invaluable level of support and comes at a key point in our development. A major challenge in the DUB field is access to novel, high-quality DUB-targeting compounds – the cornerstone of new programmes. o2h’s deep expertise in insight-driven drug discovery, synthetic chemistry, and library synthesis, combined with their established track record in accelerating early-stage drug discovery, perfectly complements our need for reliable and rapid compound synthesis and iterative optimisation. The opportunity to work closely with o2h will fast-track our progress this year and support our strategy of enabling our partners in the field of DUB-focused drug discovery.”
Sunil Shah, Co-founder, o2h discovery, said:
“As a recognised leader in supporting DUB-focused drug discovery, Ubiquigent is a worthy recipient of an o2h kickstarter award. o2h discovery is looking forward to working with the team at Ubiquigent to apply our combined technology, expertise and capabilities to the exciting DUB family of enzymes, a field which has shown considerable growth in recent years.”
Editor Notes
About Ubiquigent
Ubiquigent is a revenue and IP-generating business that enables drug discovery linked to the ubiquitin-proteasome system (UPS), with a particular focus on the rapidly emerging field of deubiquitinase (DUB) biology. Ubiquigent is the partner chosen by leading industry and academic organisations to support their drug discovery programmes spanning the development of DUB inhibitors, and modulators in the fields of protein degradation, stabilisation and cellular signalling.
The UPS and the DUB enzyme family represent an underexploited, major source of drug targets for the treatment of multiple diseases with unmet medical needs with the therapeutic exploitation of DUBs now representing a rapidly growing and accelerating global market opportunity that Ubiquigent is uniquely positioned to serve through access to a comprehensive range of assays and capabilities together with novel compound-based IP.
For more information about Ubiquigent, visit: https://www.ubiquigent.com/
About o2h discovery
Founded in 2004, o2h discovery has a multi-modality integrated drug discovery platform, operating from Cambridge, UK, and Ahmedabad, India. We have the in-house capabilities to execute hit-lead optimisation programs leading into the patent and IND filing from our state-of-the-art biotechnology incubator with expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of preclinical development.
The o2h Kickstarter competition has been designed to provide a chemistry boost to small molecule focused biotechnology companies who need to supercharge their chemistry efforts to meet their next funding milestone. Winners of this competition will receive a dedicated team of chemists and end to end project management support to generate chemical matter of their interest to meet their project milestones.
For more information about o2h discovery visit https://o2hdiscovery.co/ and for the o2h kickstarter award, visit https://o2h.com/the-o2h-kickstarter-competition/.
